Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-12-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司2023年度向特定对象发行A股股票募集资金使用的可行性分析报告（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金使用的可行性分析报告" which translates to "Feasibility Analysis Report on the Use of Raised Funds" for a specific issuance of A shares in 2023 by Jinling Pharmaceutical Co., Ltd. It details the planned use of funds raised from a targeted share issuance, including investment projects, their necessity, feasibility, expected returns, and impact on the company. The document is comprehensive and contains detailed financial and operational plans related to capital raising and fund usage. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report publication, nor is it a full annual or interim report. It is not a regulatory filing or a proxy statement. Therefore, the best classification is CAP with high confidence.
2023-12-04 Chinese
金陵药业股份有限公司2023年度向特定对象发行A股股票方案论证分析报告（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "2023 年度向特定对象发行 A 股股票方案论证分析报告" which translates to "2023 Annual Report on the Proposal and Analysis of Private Placement of A Shares." It discusses the company's plan to issue A shares to specific investors, including the background, purpose, pricing, legal compliance, fairness, and impact on shareholders. The content focuses on a capital raising activity through a private placement of shares, detailing the issuance plan, pricing methodology, regulatory compliance, and shareholder impact. There is no indication that this is a full annual report, audit report, earnings release, or other types of filings. Instead, it is a detailed capital/financing update regarding a specific share issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2023-12-04 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 100% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) for Jinling Pharmaceutical Company's 2023 private placement of A shares. It is issued by CITIC Securities as the sponsor and underwriter. The content includes detailed information about the securities issuance, the sponsor's responsibilities, legal and regulatory compliance, the issuer's background, shareholding structure, financial data, and the sponsor's internal review and recommendation for the issuance. This document is a formal sponsorship letter related to a capital raising event (private placement of shares). It is not an annual report, earnings release, or other financial report. It is not a proxy statement or voting result announcement. It is a detailed document related to a capital/financing update, specifically a private placement issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the actual sponsorship letter, not just an announcement of a report.
2023-12-04 Chinese
金陵药业股份有限公司2023年度向特定对象发行A股股票募集说明书（注册稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（注册稿）" which translates to a "Prospectus (Registration Draft)" for a specific issuance of A shares by Jinling Pharmaceutical Company Limited in 2023. It contains detailed information about the issuance, including risk factors, project descriptions, financial impacts, company background, and regulatory compliance statements. The document is lengthy (15,000 characters) and includes comprehensive disclosures typical of a securities offering prospectus. This type of document is related to capital raising activities and financing updates rather than a general annual report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-12-04 Chinese
金陵药业股份有限公司2023年第二次独立董事专门会议的审查意见
Capital/Financing Update Classification · 95% confidence The document is titled as the "2023 Second Independent Directors Special Meeting Review Opinions" of Jinling Pharmaceutical Co., Ltd. It contains detailed opinions from independent directors on various proposals related to the company's 2023 targeted issuance of A-shares, including economic benefit assessments, feasibility analysis, and related commitments. The content focuses on the independent directors' review and approval of proposals related to a capital raising activity (targeted issuance of shares). It is not a full financial report, earnings release, or regulatory filing, but rather a formal opinion document from the board's independent directors on specific financing proposals. This fits best under the category of Capital/Financing Update (CAP), as it relates to updates on company fundraising and capital structure changes. The document length is short (1579 characters), but it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2023-12-04 Chinese
关于金陵药业股份有限公司申请向特定对象发行股票的审核中心意见落实函之回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report from Jinling Pharmaceutical Co., Ltd. regarding the implementation of comments from the Shenzhen Stock Exchange on their application for a private placement of shares. It extensively discusses the proposed fundraising project, including detailed financial projections, market analysis, and operational plans for a high-end elderly care project. The content includes financial data, project feasibility, and management discussions related to the fundraising and investment project. The document is lengthy (15,000 characters) and contains substantive financial and operational information rather than merely announcing or attaching a report. It is not an annual report, earnings release, or audit report, nor is it a simple announcement or certification. The focus on the private placement and fundraising project, with detailed financial and operational analysis, aligns with a Capital/Financing Update filing type.
2023-12-04 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.